Evidence map›Paper›PMID 31109295›Full record

ArticleBMC infectious diseases2019

Seroprevalence for dengue virus in a hyperendemic area and associated socioeconomic and demographic factors using a cross-sectional design and a geostatistical approach, state of São Paulo, Brazil.

Francisco Chiaravalloti-Neto, Rafael Alves da Silva, Nathalia Zini, Gislaine Celestino Dutra da Silva, Natal Santos da Silva, Maisa Carla Pereira Parra, Margareth Regina Dibo, Cassia Fernanda Estofolete, Eliane Aparecida Fávaro, Karina Rocha Dutra and 5 more

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in BMC infectious diseases, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06891950 (Phase 3B, Double-blind, Randomized Study to Evaluate the Safety and Non-inferiority of the Humoral Immune Response of the Butantan Dengue Vaccine in Participants Aged 60 to 79 Years Compared to Participants Aged 40 to 59 Years), which is not on this map. Cited by 28 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed, 4 pooled it
5.5field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06891950 phase3recruitingnot on this mapstarted 2026, after this paper: background citation

Phase 3B, Double-blind, Randomized Study to Evaluate the Safety and Non-inferiority of the Humoral Immune Response of the Butantan Dengue Vaccine in Participants Aged 60 to 79 Years Compared to Participants Aged 40 to 59 Years

TypeinterventionalSponsorButantan InstituteRan2026 to 2027Enrolled997ConditionsDengueArmsDengue 1,2,3,4 (attenuated) vaccine
3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 4 syntheses or guidelines pooled it, 50 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Horizons of the Future: Preparedness and Response.Current topics in microbiology and immunology · 2026
    Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Dengue Seroprevalence and Factors Associated with Dengue Seropositivity in Petaling District, Malaysia.International journal of environmental research and public health · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 4 institutions in 2 countries.

Francisco Chiaravalloti-NetoDepartamento de Epidemiologia, Faculdade de Saúde Pública, Universidade de São Paulo (USP), Avenida Doutor Arnaldo 715, São Paulo, SP, 01246-904, Brazil. franciscochiara@usp.br.ORCID http://orcid.org/0000-0003-2686-8740
Rafael Alves da SilvaLaboratório de Pesquisas em Virologia, Departamento de Doenças Dermatológicas Infecciosas e Parasitárias, Faculdade de Medicina de São José do Rio Preto (FAMERP), Avenida Brigadeiro Faria Lima, 5416, São José do Rio Preto, SP, 15090-000, Brazil.
Nathalia ZiniLaboratório de Pesquisas em Virologia, Departamento de Doenças Dermatológicas Infecciosas e Parasitárias, Faculdade de Medicina de São José do Rio Preto (FAMERP), Avenida Brigadeiro Faria Lima, 5416, São José do Rio Preto, SP, 15090-000, Brazil.
Gislaine Celestino Dutra da SilvaLaboratório de Pesquisas em Virologia, Departamento de Doenças Dermatológicas Infecciosas e Parasitárias, Faculdade de Medicina de São José do Rio Preto (FAMERP), Avenida Brigadeiro Faria Lima, 5416, São José do Rio Preto, SP, 15090-000, Brazil.
Natal Santos da SilvaLaboratório de Modelagens Matemática e Estatística em Medicina, Faculdade de Medicina, União das Faculdades dos Grandes Lagos, Rua Doutor Eduardo Nielsen 960, São José do Rio Preto, SP, 15030-070, Brazil.
Maisa Carla Pereira ParraLaboratório de Pesquisas em Virologia, Departamento de Doenças Dermatológicas Infecciosas e Parasitárias, Faculdade de Medicina de São José do Rio Preto (FAMERP), Avenida Brigadeiro Faria Lima, 5416, São José do Rio Preto, SP, 15090-000, Brazil.
Margareth Regina DiboLaboratório de Entomologia, Superintendência de Controle de Endemias, Rua Cardeal Arcoverde 2878, São Paulo, SP, 05408-003, Brazil.
Cassia Fernanda EstofoleteLaboratório de Pesquisas em Virologia, Departamento de Doenças Dermatológicas Infecciosas e Parasitárias, Faculdade de Medicina de São José do Rio Preto (FAMERP), Avenida Brigadeiro Faria Lima, 5416, São José do Rio Preto, SP, 15090-000, Brazil.
Eliane Aparecida FávaroLaboratório de Pesquisas em Virologia, Departamento de Doenças Dermatológicas Infecciosas e Parasitárias, Faculdade de Medicina de São José do Rio Preto (FAMERP), Avenida Brigadeiro Faria Lima, 5416, São José do Rio Preto, SP, 15090-000, Brazil.
Karina Rocha DutraLaboratório de Pesquisas em Virologia, Departamento de Doenças Dermatológicas Infecciosas e Parasitárias, Faculdade de Medicina de São José do Rio Preto (FAMERP), Avenida Brigadeiro Faria Lima, 5416, São José do Rio Preto, SP, 15090-000, Brazil.
Manlio Tasso Oliveira MotaLaboratório de Pesquisas em Virologia, Departamento de Doenças Dermatológicas Infecciosas e Parasitárias, Faculdade de Medicina de São José do Rio Preto (FAMERP), Avenida Brigadeiro Faria Lima, 5416, São José do Rio Preto, SP, 15090-000, Brazil.
Georgia Freitas GuimarãesLaboratório de Pesquisas em Virologia, Departamento de Doenças Dermatológicas Infecciosas e Parasitárias, Faculdade de Medicina de São José do Rio Preto (FAMERP), Avenida Brigadeiro Faria Lima, 5416, São José do Rio Preto, SP, 15090-000, Brazil.
Ana Carolina Bernardes TerzianLaboratório de Pesquisas em Virologia, Departamento de Doenças Dermatológicas Infecciosas e Parasitárias, Faculdade de Medicina de São José do Rio Preto (FAMERP), Avenida Brigadeiro Faria Lima, 5416, São José do Rio Preto, SP, 15090-000, Brazil.
Marta BlangiardoMRC-PHE Centre for Environment and Health, Department of Epidemiology and Biostatistics, Imperial College, St. Mary's Campus, Norfolk Place, London, W2 1PG, UK.
Mauricio Lacerda NogueiraLaboratório de Pesquisas em Virologia, Departamento de Doenças Dermatológicas Infecciosas e Parasitárias, Faculdade de Medicina de São José do Rio Preto (FAMERP), Avenida Brigadeiro Faria Lima, 5416, São José do Rio Preto, SP, 15090-000, Brazil.
Faculdade de Medicina de São José do Rio Preto · BRDepartamento de Ciência e Tecnologia · BRMRC Centre for Environment and HealthUniversidade de São Paulo · BR

Funding

Medical Research Council MR/S019669/1
6 · The paper itself

Abstract

backgroundSão José do Rio Preto is one of the cities of the state of São Paulo, Brazil, that is hyperendemic for dengue, with the presence of the four dengue serotypes.

objectivesto calculate dengue seroprevalence in a neighbourhood of São José do Rio Preto and identify if socioeconomic and demographic covariates are associated with dengue seropositivity.

methodsA cohort study to evaluate dengue seroprevalence and incidence and associated factors on people aged 10 years or older, was assembled in Vila Toninho neighbourhood, São José do Rio Preto. The participant enrolment occurred from October 2015 to March 2016 (the first wave of the cohort study), when blood samples were collected for serological test (ELISA IgG anti-DENV) and questionnaires were administrated on socio-demographic variables. We evaluated the data collected in this first wave using a cross-sectional design. We considered seropositive the participants that were positive in the serological test (seronegative otherwise). We modelled the seroprevalence with a logistic regression in a geostatistical approach. The Bayesian inference was made using integrated nested Laplace approximations (INLA) coupled with the Stochastic Partial Differential Equation method (SPDE).

resultsWe found 986 seropositive individuals for DENV in 1322 individuals surveyed in the study area in the first wave of the cohort study, corresponding to a seroprevalence of 74.6% (95%CI: 72.2-76.9). Between the population that said never had dengue fever, 68.4% (566/828) were dengue seropositive. Older people, non-white and living in a house (instead of in an apartment), were positively associated with dengue seropositivity. We adjusted for the other socioeconomic and demographic covariates, and accounted for residual spatial dependence between observations, which was found to present up to 800 m.

conclusionsOnly one in four people aged 10 years or older did not have contact with any of the serotypes of dengue virus in Vila Toninho neighbourhood in São José do Rio Preto. Age, race and type of house were associated with the occurrence of the disease. The use of INLA in a geostatistical approach in a Bayesian context allowed us to take into account the spatial dependence between the observations and identify the associated covariates to dengue seroprevalence.

Indexed as

AdolescentAdultAgedAged, 80 and overAntibodies, ViralBrazilCohort StudiesCross-Sectional StudiesDemographyDengueDengue VirusFemaleHumansIncidenceMaleMiddle AgedAntibodies, ViralBrazilCross-sectional studyDengueGeostatiscal analysisSeroprevalence

Identifiers

PMID31109295
PMCPMC6528304
OpenAlexW2947782947

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.